Last updated: May 24, 2026
Executive summary
Macitentan (MACITENTAN) is an endothelin receptor antagonist used in pulmonary arterial hypertension and is supplied through a mix of API manufacturers, intermediate producers, and contract manufacturing organizations (CMOs). Tadalafil (TADALAFIL) is a PDE5 inhibitor supplied at higher global scale for erectile dysfunction, BPH, and pulmonary indications, with a broader API and finished-dose manufacturing ecosystem. Both APIs are routinely sourced from multiple China- and India-based API suppliers and are also supplied via branded originators and licensed partners.
Which companies supply macitentan API (and related intermediates)?
Macitentan is typically supplied as the drug substance (API) by a limited set of established high-quality API manufacturers and via intermediate supply chains that feed finished-dose CMOs.
API supply chain structure (how it typically sources)
- Drug substance: macitentan API
- Upstream: key intermediates used to assemble the macitentan core and final purification steps
- Finished dose: macitentan 10 mg tablets (most common market presentation)
Common supplier categories
- High-compliance API manufacturers (cGMP/ICH-aligned operations)
- Fee-for-service intermediate producers supplying specific steps under controlled specs
- Finished-dose/tablet CMOs for market release
What to verify in due diligence
- DMF status (US FDA Drug Master File) or equivalent filings in target jurisdictions
- Particle size, polymorph control, and impurity profiles for macitentan
- Demonstrated ability to supply under multiple market schedules (commercial + tenders)
Who supplies tadalafil API and finished dosage tablets?
Tadalafil has a more distributed supply footprint than macitentan because of scale and multi-indication use. API supply and finished-dose manufacturing for tadalafil is broad, with many qualified suppliers across major generic markets.
API supply chain structure
- Tadalafil API
- Optional upstream intermediate supply for cost and timeline control
- Tablet strength variants depending on market (commonly 2.5 mg, 5 mg, 10 mg, 20 mg; exact local formats vary)
Due diligence checkpoints
- Establish origin of API (manufacturer of record vs reseller)
- Check impurity specs tied to the DMF or manufacturing site
- Verify compression/tableting suitability for excipient systems used by the finished-dose CMO
What excipient and tablet-finish suppliers matter for macitentan tablets?
Macitentan tablets require excipient systems that maintain stability and allow consistent dissolution and bioavailability.
Finished-dose inputs that CMOs typically control
- Direct compression or granulation-grade fillers
- Binders for tablet cohesion
- Disintegrants for dissolution
- Lubricants and anti-adherents
- Coating materials (if used for the specific marketed tablet)
Where suppliers show up in sourcing
- Excipients sold by global specialty excipient firms to CMOs
- CMO-selected excipient packages tied to validated processes
What excipient and coating suppliers matter for tadalafil tablets?
Tadalafil tablets can be manufactured using multiple process routes depending on strength and local product design. Key excipient roles are similar across markets, but supplier lists are often tied to validated CMO formulation packages.
Critical excipient categories
- Fillers and binders
- Disintegrants
- Lubricants
- Coating polymer and pigment package (if coated)
What to check
- Compatibility with tadalafil API (stability and impurity formation)
- Tablet hardness and dissolution specifications at each strength
- Regulatory acceptance for excipient grades in each target geography
How do contract manufacturing organizations (CMOs) source macitentan vs tadalafil?
Macitentan sourcing pattern
- Higher dependence on a small number of qualified drug substance sources
- More frequent reliance on DMF-linked API supply for regulated markets
- Finished-dose CMOs commonly lock formulation and API control strategy early
Tadalafil sourcing pattern
- More redundant qualified API supplier base
- Finished-dose CMOs can switch API sources if bridging and regulatory documentation are completed
- Higher manufacturing volume supports more supply options
What licensing or authorized supply constraints apply to macitentan?
Macitentan supply for regulated markets can be constrained by:
- Originator-controlled drug substance supply channels
- Market-specific authorized manufacturing slots
- Regulatory dependence on specific DMF references and site approvals
In practice, authorized supply matters most for:
- US and EU launches that rely on specific reference filings
- Tender-driven supply where documentation packages are scrutinized
What licensing or authorized supply constraints apply to tadalafil?
Tadalafil is broadly available due to market maturity, which reduces single-channel risk. Constraints tend to be:
- IP-related formulation or process controls on specific generic products
- Regulatory documentation and validation requirements for changing API source
- Supply continuity commitments in long-term commercial agreements
Key comparison: macitentan vs tadalafil supplier ecosystem
| Dimension |
Macitentan |
Tadalafil |
| Typical API supply footprint |
Narrower, quality-constrained |
Wider, higher redundancy |
| Finished-dose prevalence |
Lower number of products |
More strengths and formats globally |
| Sensitivity to DMF-linked sourcing |
Higher |
Moderate to high (depends on jurisdiction/product) |
| Supply-chain bottlenecks |
Upstream intermediate availability and impurity control |
Volume-driven capacity and excipient availability |
What generic entry risks change supplier selection for macitentan?
For macitentan, supplier selection often includes:
- IP risk screening for method-of-use and formulation patents (where applicable)
- Regulatory risk tied to DMF reference and impurity control
- Supply continuity plans to avoid requalification delays
What generic entry risks change supplier selection for tadalafil?
Tadalafil has more generic competition, so suppliers focus on:
- Ensuring regulatory-ready API quality and consistent impurity profile
- Process validation readiness at the CMO
- Ability to pass bioequivalence bridging if API source changes
Key takeaways
- Macitentan supply is typically more constrained by drug substance qualification, impurity control, and regulated-market documentation requirements.
- Tadalafil supply has a broader and more redundant API and finished-dose manufacturing ecosystem due to scale.
- In both cases, the decisive supplier-selection criteria are DMF-linked documentation, site qualification, impurity profile control, and CMO process validation readiness.
FAQs
- How do I identify the true macitentan API manufacturer of record versus distributors?
- Which DMF-linked API sources are commonly required for macitentan in US or EU filings?
- Can tadalafil finished-dose CMOs switch tadalafil API suppliers without revalidation issues?
- What impurity and polymorph controls matter most for macitentan API qualification?
- How do tender documentation requirements affect macitentan and tadalafil supplier eligibility?
References
No sources were provided or cited in the input.
